Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardiome/Astellas Schedule Kynapid Meeting With FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Meanwhile, Astellas yanks its Canadian new drug submission for the atrial fibrillation candidate to align its North American regulatory strategy.

You may also be interested in...



Merck Pumps Pipeline With $800M Cardiome Deal

FDA-delayed vernakalant for atrial fibrillation nets handsome pact, as more-lucrative oral form awaits Phase III trials.

Merck Pumps Pipeline With $800M Cardiome Deal

FDA-delayed vernakalant for atrial fibrillation nets handsome pact, as more-lucrative oral form awaits Phase III trials.

Astellas Bows Out Of The CVT Sweepstakes, But What’s Next?

Japanese pharma drops lawsuit, ends its bid to buy cardiovascular-focused U.S. biotech, and hunts for other possibilities.

Related Content

Topics

UsernamePublicRestriction

Register

PS066865

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel